APA (7th ed.) Citation

Conaghan, P., Cohen, S., Burmester, G., Mysler, E., Nash, P., Tanaka, Y., . . . Fleischmann, R. (2022). Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. Rheumatology & Therapy, 9(1), 191. https://doi.org/10.1007/s40744-021-00399-5

Chicago Style (17th ed.) Citation

Conaghan, Philip, et al. "Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis." Rheumatology & Therapy 9, no. 1 (2022): 191. https://doi.org/10.1007/s40744-021-00399-5.

MLA (9th ed.) Citation

Conaghan, Philip, et al. "Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis." Rheumatology & Therapy, vol. 9, no. 1, 2022, p. 191, https://doi.org/10.1007/s40744-021-00399-5.